Bruker Introduces Novel Point-of-Need Applied Mass Spectrometry Tools for Accelerated Measurements without Chromatography
June 06 2022 - 7:00AM
Business Wire
- Recent acquisition of DART™ (Direct Analysis Real-time
Technology) innovator IonSense extends Bruker’s unique
Point-of-Need (PoN) mass spectrometers
- Launch of DART-EVOQ® triple quadrupole mass spectrometer
offers simple, robust, yet sensitive and specific PoN workflows for
applied markets
- New Bruker strategic partnership with TOFWERK AG brings
together skills and vision for next-generation high-speed,
ultra-sensitive analytical solutions
At ASMS 2022, Bruker Corporation (Nasdaq: BRKR) extends the
power of mass spectrometry inside and outside the laboratory to
Point-of-Need (PoN) analysis with the introduction of the
DART-EVOQ® triple quadrupole mass spectrometer for
high-throughput quantitative analyses. The DART-EVOQ does not
require chromatography separations for applied markets analysis in
food/beverage, forensics, industrial, security, environmental and
pharmaceutical workflows.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220606005371/en/
DART-EVOQ PoN Mass Spec (Photo: Business
Wire)
In April 2022, Bruker acquired IonSense, a leader in ambient
ionization and developer of the DART™ ionization source that
can analyze many types of samples, including solids, liquids and
gases, in seconds with little to no sample preparation prior to
analysis. DART technology removes time-consuming steps to rapidly
identify and quantify sample analytes. DART enables novel PoN
workflows that are challenging for conventional GC- and LC-mass
specs because of the complexity, long analysis times and reduced
robustness of front-end chromatography that is required for complex
mixture analysis.
With DART in its portfolio, Bruker announces first applications
with the launch of the DART-EVOQ system that extends applicability
and performance for fast PoN mass spec measurements. DART-EVOQ
users can rapidly identify samples, including many that do not
ionize well using other methods. Innovative applications for
combined DART-triple quad mass spectrometry include trace level
volatile quantitation in grape harvests.
Dr. Gavin Sacks, Department of Food Science at Cornell
University, observed: “The good correlations between GC-MS and
DART-MS data suggest that the latter could be used as a rapid
point-of-need alternative with ~30 sec/sample, compared to
conventional GC-MS with typically ~30 min/sample analysis times.
The combination of DART with triple quad mass spectrometers brings
the potential of highly sensitive and selective point-of-need
analyses into the hands of a broader range of users.”
In May 2022, Bruker announced a strategic partnership with
TOFWERK AG for high-speed, ultra-sensitive applied and industrial
analytical solutions, in conjunction with a Bruker minority
investment. TOFWERK’s instruments are used in applications such as
ambient air monitoring, breath analysis (for research use only),
food and flavor analysis, and for airborne molecular contamination
(AMC) monitoring in the semiconductor industry.
Dr. Marc Gonin, co-founder and CEO of TOFWERK, said: “We are
excited to work closely with Bruker and IonSense to further
accelerate the commercialization of compact, high-speed TOF-MS
solutions for industrial and applied markets, based on ultra-high
sensitivity and point-of-need analysis technologies developed at
TOFWERK and Bruker.”
Bruker has a strong heritage in mass spectrometry in life
sciences and applied markets such as food, environmental,
forensics, industrial and clinical, e.g., with the MALDI Biotyper™
as the leading clinical mass spectrometry platform, with over 5000
systems in use in microbiology worldwide.
“Our expertise in developing novel workflows to overcome
challenges faced by our customers is second to none,” commented
Juergen Srega, the Bruker CALID Group President. “Our new
Point-of-Need introductions again extend mass spec capabilities
beyond traditional laboratory settings. We aim to be a leader in
PoN mass spec solutions that enable simple and fast analyses,
wherever they are needed. Our strategic investments, and the launch
of the DART-EVOQ are important steps towards this goal.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular, and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity, and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. Please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220606005371/en/
Media Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Investor Relations Justin Ward Sr. Director Investor
Relations & Corp Development T: +1 (978) 663–3660, ext. 1479 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024